NCT02789111View on ClinicalTrials.gov

Trial of Alvimopan in Major Spine Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

December 1, 2018

Study Completion Date

December 1, 2018

Conditions
Constipation
Interventions
DRUG

Alvimopan

Alviimopan 12 mg twice daily up to 15 doses

DRUG

Placebo

Placebo twice daily up to 15 doses

Trial Locations (1)

22908

University of Virginia, Charlottesville

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Virginia

OTHER

NCT02789111 - Trial of Alvimopan in Major Spine Surgery | Biotech Hunter | Biotech Hunter